FPE-021

N/A

Report date: 2026/03/19 17:12:04

Base Information

Drug NameFPE-021
Drug Alias NameFPE-021
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCadherin-17 modulatorsT-cell-specific surface glycoprotein CD28 modulatorsT cell surface glycoprotein CD3 modulators +[4] 
TargetsCadherin-17T-cell-specific surface glycoprotein CD28T cell surface glycoprotein CD3 +[4] 
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangdong Fapon Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Fapon Biopharma Inc
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A